aggressive NK/T cell lymphoma (Extranodal NK/T cell lymphoma, nasal type
Conditions
Interventions
Treatment group:Gemcitabine 800mg/m^2 Day1, 8
L-ASP 6000mg/m^2 Day 8, 10, 12, 14, 16, 18, 20
isophosphomide 1g/m^2 Day 1-3
Dexamethasone 40mg Day 1-4, Day 9-12 (prednisone 100mg Day 1-5 for first cyle of gastrointestianl lymphoma)
etopside 100mg//m^2 Day 1-3. 6 to 8 cycles in total
Sponsors
West China Hospital
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of aggressive NK/T cell lymphoma by histology and immunochemistry based on WHO 2008. Stage I and II lymphoma will not be permitted to enter study; 2. Eastern Cooperative Oncology Group (ECOG) status 0-2; 3. All patients have to sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study; 4. Estimated survival time > 3 months.
Exclusion criteria
Exclusion criteria: 1. Pregnent or breast-feeding women; 2. Active systemic infection requiring treatment and patients with known diagnosis of HIV or active hepatitis B; 3. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-years disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete response rate;overall response rate;2-year overall survival;grade III and IV adverse event; | — |
Countries
China
Contacts
Public ContactJie Ji
Department of Hematology, West China Hospital, SCU
Outcome results
None listed